The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | Patterns of relapse after commercial use of anti-CD19 CAR-T in patients with R/R DLBCL
Alberto Mussetti, MD, Institut Catala d’Oncologia Hospitalet, Barcelona, Spain, comments on the patterns of relapse after commercial use of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). A retrospective real-world study found that this cohort of patients is highly heterogeneous, with different types of relapse occurring at varying times after CAR-T infusion. This includes late relapses (after 6 months) and high-risk relapses (within 2 months), which have a significant impact on survival. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In the recent study that we are presenting at this meeting that we did with the collaboration with the European registry, we confirmed data which already have been observed from other national registries, but with a prolonged follow-up and with a larger cohort of patients.
So basically the principal observation that we did from the study is that of course the majority of the patients receiving anti-CD19 CAR-T cell therapy as a third line or further line of therapy will relapse, eventually, between 50 to 60 percent of these patients will have a relapse...
In the recent study that we are presenting at this meeting that we did with the collaboration with the European registry, we confirmed data which already have been observed from other national registries, but with a prolonged follow-up and with a larger cohort of patients.
So basically the principal observation that we did from the study is that of course the majority of the patients receiving anti-CD19 CAR-T cell therapy as a third line or further line of therapy will relapse, eventually, between 50 to 60 percent of these patients will have a relapse. But of course there are different types of relapse. So the topic and the issue of the relapse after CAR-T is an actual clinical need and an active area of investigation. And so it is very different from what we observed from this real-life study how different centers and different doctors are treating such kind of relapses, which are very different in themselves. We observed a cohort of patients who have a late relapse, defined as having a relapse after six months from the infusion, and then we have another very high-risk cohort of patients relapsing between two months from the CAR-T infusion and this has an impact on the survival from the relapse. So this is what we observe, an heterogeneous cohort of disease relapse and an heterogeneous way to treat such relapses also in Europe.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honoraria for lectures: Takeda, BMS, Gilead, Sanofi; Honoraria for advisory board activities: Merck, Jazz Pharma; Participation in clinical trials (PI): Atara, Takeda; Research funding: Gilead.
